Drug Safety

, Volume 6, Issue 1, pp 1–7 | Cite as

The Potential of Biotechnology to Improve the Quality of Life of Patients with Renal Failure

  • Wendy E. Bloembergen
  • Andreas Laupacis
Leading Article


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aaronson NK, Quality of life assessment in clinical trials: methodologic issues. Controlled Clinical Trials 10: 195S–208S, 1989PubMedCrossRefGoogle Scholar
  2. Adamson JW, Eschbach JW, Finch CA. The kidney and crythropoiesis. American Journal of Medicine 44: 725–733, 1968PubMedCrossRefGoogle Scholar
  3. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Medical Care 19: 787–805, 1981PubMedCrossRefGoogle Scholar
  4. Bombardier C, Ware J, Russell IJ, Larson M, Chalmers A, et al. Auranofin therapy and quality of life in patients with rheumatoid arthritis: results of a multicenter trial. American Journal of Medicine 81: 565–578, 1986PubMedCrossRefGoogle Scholar
  5. Bommer J, Kugel M, Schobel B, Ritz E, Barth HP, et al. Improved sexual function during recombinant human erythropoietin therapy. Nephrology Dialysis Transplantation 5: 204–207, 1990Google Scholar
  6. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. British Medical Journal 300: 573–578, 1990CrossRefGoogle Scholar
  7. Cantarovich D, Le Mauff B, Hourmant M, Peyronnet P, Jacques Y, et al. Prophylactic use of a monoclonal antibody (33B3.1) directed against interleukin 2 receptor following human renal transplantation. American Journal of Kidney Diseases 11: 101–106, 1988PubMedGoogle Scholar
  8. Churchill DN, Torrance GW, Taylor DW, Barnes CC, Ludwin D, et al. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clinical and Investigative Medicine 10: 14–20, 1987PubMedGoogle Scholar
  9. Colvin RB. Clinical applications of monoclonal antibodies in renal allograft biopsies. American Journal of Kidney Diseases 11: 126–130, 1988PubMedGoogle Scholar
  10. Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, et al. The effects of antihypertensive therapy on the quality of life. New England Journal of Medicine 314: 1657–1664, 1986PubMedCrossRefGoogle Scholar
  11. DeBure A, Chkoff N, Chatenoud L, Lacombe M, Campos H, et al. One-month prophylactic use of OKT3 in cadaver kidney transplant recipients. Transplantation 45: 546–553, 1988PubMedCrossRefGoogle Scholar
  12. Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. American Journal of Kidney Diseases 14 (Suppl. 1): 14–18, 1989PubMedGoogle Scholar
  13. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney International 35: 134–148, 1989PubMedCrossRefGoogle Scholar
  14. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Annals of Internal Medicine 111: 992–1000, 1989PubMedGoogle Scholar
  15. Eschbach JW, Adamson JW. Recombinant human erythropoietin: implications for nephrology. American Journal of Kidney Diseases 11: 203–209, 1988PubMedGoogle Scholar
  16. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. New England Journal of Medicine 316: 73–78, 1987PubMedCrossRefGoogle Scholar
  17. Evans RW, Manninen DL, Garrison LP, Hart LG, Blagg CR, et al. The quality of life with end-stage renal disease. New England Journal of Medicine 312: 553–559, 1985PubMedCrossRefGoogle Scholar
  18. Evans RW, Rader B, Manninen DL, Cooperative Multicenter EPO Clinical Trial Group. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Journal of the American Medical Association 263: 825–830, 1990PubMedCrossRefGoogle Scholar
  19. Ganz PA. Methods of assessing the effect of drug therapy on quality of life. Drug Safety 5: 233–242, 1990PubMedCrossRefGoogle Scholar
  20. Ginn HE, Teschan PE. The quality of life of the chronic dialysis patient. In Drukker et al. (Eds) Replacement of renal function by dialysis, pp. 837–843, Martinus Nijhoff Publishers, Boston, 1983CrossRefGoogle Scholar
  21. Guyatt GH, Bombardier C, Tugwell P. Measuring disease-specific quality of life in clinical trials. Canadian Medical Association Journal 134: 889–895, 1986PubMedGoogle Scholar
  22. Guyatt GH, Thompson PJ, Berman LB, Sullivan MJ, Townsend M, et al. How should we measure function in patients with chronic heart and lung disease? Journal of Chronic Diseases 38: 517–524, 1985PubMedCrossRefGoogle Scholar
  23. Guyatt GH, Veldhuyzen Van Zanten SJO, Feeny DH, Patrick DL. Measuring quality of life in clinical trials: a taxonomy and review. Canadian Medical Association Journal 140: 1441–1448, 1989PubMedGoogle Scholar
  24. Hart LG, Evans RW. The functional status of ESRD patients as measured by the Sickness Impact Profile. Journal of Chronic Disease 40 (Suppl. 1): 117S–130S, 1987CrossRefGoogle Scholar
  25. Helderman JH. Summary: diagnostic uses. American Journal of Kidney Diseases 11: 134, 1988aGoogle Scholar
  26. Helderman JH. The use of monoclonal antibodies in fine needle aspiration biopsy of the renal transplant. American Journal of Kidney Diseases 11: 131–133, 1988bPubMedGoogle Scholar
  27. Imagawa A, Kawanishi Y, Numata A. Is erythropoietin effective for impotence in dialysis patients? Nephron 54: 95–96, 1990PubMedCrossRefGoogle Scholar
  28. Jacobs K, Shoemaker C. Rudersdorf R, Neill SD, Kaufman RJ, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313: 806–810, 1985PubMedCrossRefGoogle Scholar
  29. Jaffers GJ, Cosimi AB. Antilymphocyte globulin and monoclonal antibodies. In Morris PJ (Ed.) Kidney transplantation: principles and practice. 2nd ed., pp. 290–291, Grune & Stratton, Orlando, 1984Google Scholar
  30. Johnson JP. McCaulcy CR, Copley JB. The quality of life of hemodialysis and transplant patients. Kidney International 22: 286–291. 1982PubMedCrossRefGoogle Scholar
  31. Kirkman RL, Araujo JL, Busch GJ, Carpenter CB, Milford EL, et al. Treatment of acute renal allograft rejection with monoclonal anti-T12 antibody. Transplantation 36: 620–626, 1983PubMedCrossRefGoogle Scholar
  32. Kutner NG, Brogan D, Kutner MH. End-stage renal disease treatment modality and patients’ quality of life. American Journal of Nephrology 6: 396–402, 1986PubMedCrossRefGoogle Scholar
  33. Laupacis A, Muirhead N, Wong C, Canadian Erythropoietin Study Group. The effect of recombinant human erythropoeitin (EPO) upon quality of life (QOL) of anemic hemodialysis (HD) patients during eighteen months of follow-up. Clinical and Investigative Medicine 13 (Suppl. 1): B72, 1990Google Scholar
  34. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, et al. Cloning and expression of the human erythropoietin gene. Proceedings of the National Academy of the Sciences of the United States of America 82: 7580–7585, 1985CrossRefGoogle Scholar
  35. Lundin PA. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy. Seminars in Nephrology 9 (Suppl. 1): 22–29, 1989PubMedGoogle Scholar
  36. Mayer G, Thum J, Cada EM, Stummvoll HK, Graf H. Working capacity is increased following recombinant human erythropoietin treatment. Kidney International 34: 525–528, 1988PubMedCrossRefGoogle Scholar
  37. Miyake T, Kung CKH, Goldwasser E. Purification of human erythropoietin. Journal of Biological Chemistry 252: 5558–5564, 1977PubMedGoogle Scholar
  38. Murphy JR, Kelley VE, Strom TB. Interleukin 2 toxin; a step toward selective immunomodulation. American Journal of Kidney Diseases 11: 159–162, 1988PubMedGoogle Scholar
  39. Norman DJ, Barry JM, Bennett WM, Leone M, Henell K, et al. The use of OKT3 in cadaveric renal transplantation for rejeclion that is unresponsive to conventional anti-rejection therapy. American Journal of Kidney Diseases 11: 90–93, 1988aPubMedGoogle Scholar
  40. Norman DJ, Shield CF, Barry J, Bennett WM, Henell K, et al. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection. American Journal of Kidney Diseases 11: 107–110, 1988bPubMedGoogle Scholar
  41. Ortho Multicentcr Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. New England Journal of Medicine 313: 337–342, 1985CrossRefGoogle Scholar
  42. Schaefcr RM, Kokot F, Wernze H, Geiger H, Heidland A. Improved sexual function in hemodialysis patients on rccombinant erythropoietin: a possible role for prolactin. Clinical Nephrology 31: 1–5, 1989Google Scholar
  43. Sheingold SH, Churchill DN, Muirhead N, Laupacis A. Recombinant human erythropoietin: factors to consider in cost-benefit analysis. American Journal of Kidney Diseases, in press, 1990Google Scholar
  44. Simmons RG, Abress L. Quality of life and rehabilitation differences among alternate end-stage renal disease therapies. Transplantation Proceedings 20 (Suppl. 1): 379–380, 1988Google Scholar
  45. Simmons RG, Anderson C, Kamstra L. Comparison of quality of life of patients on continuous ambulatory peritoneal dialysis, hemodialysis, and after transplantation. American Journal of Kidney Diseases 4: 253–255, 1984PubMedGoogle Scholar
  46. Smith GR, O’Rourke DF. Return to work after a first myocardial infarction: a test of multiple hypotheses. Journal of the American Medical Association 259: 1673–1677, 1988PubMedCrossRefGoogle Scholar
  47. Soulillou JP, Cantarovich D, Le Mauff B. Giral M, Robillard N, et al. Randomized controlled trial of a monoclonal antibody against the intcrleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. New England Journal of Medicine 322: 1175–1182, 1990PubMedCrossRefGoogle Scholar
  48. Strom TB. Summary: today’s biotechnology and tomorrow’s antirejection therapy. American Journal of Kidney Diseases 11: 163–165, 1988Google Scholar
  49. Terasaki P, Cats S, Cicciarelli J, Toyotome A, Iwaki Y, et al. Use of monoclonal antibodies for kidney transplant patients. Transplantation Proceedings 17: 1521–1525, 1985Google Scholar
  50. Thistlethwaite JR, Gaber AO, Haag BW. Aronson AJ, Broelsch CE, et al. OKT3 treatment of steroid-resistant renal allograft rejection. Transplantation 43: 176–184, 1987PubMedCrossRefGoogle Scholar
  51. Thistlethwaite R, Kahana L, Monaco A, Norman D, Shield C, et al. Early prophylaxis with orthoclone OKT3 versus conventional therapy in renal transplant patients. XIII International Congress of the Transplantation Society, Symposium and Poster Abstracts, p. 106, 1990Google Scholar
  52. Thistlethwaite JR, Stuart JM, Mayes JT. Gaber AO, Woodle S. Complications and monitoring of OKT3 therapy. American Journal of Kidney Diseases 11: 112–119, 1988PubMedGoogle Scholar
  53. Thurlow PJ, Lovering E, D’Apice AJF, McKenzie IFC. A monoclonal anti-pan-t-cell antibody. Transplantation 36: 293–298, 1983PubMedCrossRefGoogle Scholar
  54. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, et al. Effect of human erythropoietin derived from recombinant DNA of the anemia of patients maintained by chronic haemodialysis. Lancet 2: 1175–1177, 1986PubMedCrossRefGoogle Scholar
  55. Wolcott DL, Marsh JT, La Rue A, Carr C, Nissenson AR. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. American Journal of Kidney Diseases 14: 478–485, 1989PubMedGoogle Scholar
  56. World Health Organization. Constitution in basic documents. World Health Organization, Geneva, 1948Google Scholar

Copyright information

© Adis International Limited 1991

Authors and Affiliations

  • Wendy E. Bloembergen
    • 1
  • Andreas Laupacis
    • 1
  1. 1.Department of Medicine and Department of Epidemiology and BiostatisticsUniversity of Western OntarioLondonCanada

Personalised recommendations